There are now several immunotherapies capable of clearing amyloid-β aggregates from the aging brain, and a sizable amount of clinical trial data to look through. Sadly, this approach doesn’t much help patients in the later stages of Alzheimer’s disease, but the evidence to date suggests that it may be useful in prevention if the clearance is conducted early enough. Amyloid-β aggregation causes mild cognitive impairment in and of itself, but really just sets the stage for a set of different processes, inflammation and <a href="https://en.wikipedia.org/wiki/Neurofi…
Thoughts on What is Revealed in the Trial Data for Amyloid-β Clearance
There are now several immunotherapies capable of clearing amyloid-β aggregates from the aging brain, and a sizable amount of clinical trial data to look through. Sadly, this approach doesn’t much help patients in the later stages of Alzheimer’s disease, but the evidence to date suggests that it may be useful in prevention if the clearance is conducted early enough. Amyloid-β aggregation causes mild cognitive impairment in and of itself, but really just sets the stage for a set of different processes, inflammation and <a href="https://en.wikipedia.org/wiki/Neurofi…